Latanoprost : an update of its use in @entity726 and XXXX .

@entity1 @entity1538 @entity6839 @entity15438 @entity726 @entity2134 @entity16495 @entity2790 @entity3774 @entity3169 @entity13507 @entity2747 @entity42316
Latanoprost (Xalatan) is an @entity13507 analogue of @entity3774 that reduces intraocular pressure (IOP) by increasing uveoscleral outflow. The IOP-lowering efficacy of latanoprost 0.005% lasts for up to 24 hours after a single topical dose, which allows for a once-daily dosage regimen. In @entity1 with @entity2790 or @entity1538 , a single drop of latanoprost 0.005% solution (about 1.5 microg) administered topically once daily reduced diurnal IOP by 22 to 39% over 1 to 12 months' treatment in well-controlled trials; efficacy was maintained during treatment periods of up to 2 years. At this dosage, latanoprost was significantly more effective than @entity6839 0.5% twice daily in 3 of 4 large, double-blind, randomised studies, was generally as effective as bimatoprost or travoprost, and was significantly more effective than @entity15438 , @entity16495 or @entity42316 . Furthermore, in @entity1 whose IOP was poorly controlled with @entity6839 , switching to latanoprost monotherapy was at least as effective at lowering IOP as adding @entity15438 or @entity2134 to the regimen. Latanoprost has also shown significant additive effects when used in combination with one or more @entity726 medications. The fixed combination of latanoprost plus @entity6839 was significantly more effective than either of its individual components in two double-blind randomised studies and more effective than the fixed combination of @entity15438 and @entity6839 in a 3-month, evaluator-masked study. Data in @entity1 with @entity2747 are limited, but in @entity1 with elevated IOP after undergoing iridotomy, latanoprost 0.005% once daily was significantly more effective than @entity6839 0.5% twice daily at reducing IOP over 12 weeks of treatment in a large double-blind, randomised study. Latanoprost is generally well tolerated and, unlike @entity6839 , induces minimal systemic adverse events. In well-controlled, 6-month trials, the most commonly occurring drug-related ocular events in latanoprost recipients were mild to moderate @entity3169 (3 to 15%) and iris colour change (2 to 9%); these seldom required @entity1 withdrawal although the latter may be permanent. Latanoprost 0.005% as a single daily drop has shown good IOP-lowering efficacy in @entity1 with @entity1538 or @entity2790 and does not produce the cardiopulmonary adverse effects associated with beta-blockers. Thus, latanoprost is a valuable addition to the first-line treatment options for @entity1 with @entity1538 or @entity2790 . In addition, adjunctive treatment with latanoprost in @entity1 who are refractory to beta-blocker therapy is a viable, second-line treatment option. Although preliminary findings are promising, wider clinical experience is required to define the place of latanoprost in the treatment of @entity2747 .
